https://assets.capyfin.com/instruments/678fdc13234e27009c5d6327.png avatar
ClearPoint Neuro
🇺🇸 NASDAQ:CLPT
View Company
OverviewEarningsDividends
•
Sep 30, 2022

ClearPoint Neuro Q3 2022 Earnings Report

Reported a revenue increase of 13% year-over-year, driven by growth in functional neurosurgery navigation and therapy revenue, biologics and drug delivery revenue, and capital equipment and software revenue.

Key Takeaways

ClearPoint Neuro reported a strong third quarter with a 13% increase in revenue year-over-year, reaching $5.1 million. The company reaffirmed its full-year 2022 revenue outlook of $21.0 to $22.0 million and highlighted the European Commission's marketing authorization for Upstaza, a gene therapy treatment to be administered with ClearPoint's SmartFlow® Neuro Cannula.

Reported quarterly revenue of $5.1 million, a 13% year-over-year increase.

Partner PTC Therapeutics’ gene therapy treatment Upstaza™ was granted full marketing authorization by the European Commission.

Added multiple new biologics and drug delivery partners in the quarter to bring the total to approximately 50.

Announced multiple FDA clearances: the ClearPoint Maestro™ Brain Model, the ClearPoint Prism™ Neuro Laser Therapy System and the 2.1 version of the ClearPoint Neuro Navigation software.

Total Revenue
$5.15M
Previous year: $4.57M
+12.5%
EPS
-$0.15
Previous year: -$0.18
-16.7%
Gross Margin
72%
Gross Profit
$3.71M
Previous year: $3.04M
+22.1%
Cash and Equivalents
$18.7M
Previous year: $57.7M
-67.5%
Free Cash Flow
-$3.92M
Previous year: -$3.42M
+14.6%
Total Assets
$57.7M
Previous year: $68.7M
-16.0%

ClearPoint Neuro

ClearPoint Neuro

ClearPoint Neuro Revenue by Segment

Forward Guidance

The Company reaffirms its full year 2022 revenue outlook of between $21.0 and $22.0 million.

Revenue & Expenses

Visualization of income flow from segment revenue to net income

Company Overview

Full financial data and analysis

View ClearPoint Neuro